Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
side decrease » sizes decrease (Expand Search), fid decreased (Expand Search), step decrease (Expand Search)
Showing 161 - 180 results of 21,342 for search '(( significant ((side decrease) OR (mean decrease)) ) OR ( significant decrease decrease ))', query time: 0.61s Refine Results
  1. 161
    No significant diurnal rhythmicity of short chain fatty acids in the blood was observed.

    No significant diurnal rhythmicity of short chain fatty acids in the blood was observed. by Weiran Shan (16969688)

    Published 2025
    Save to List
    Saved in:
  2. 162
    The mean and standard deviation of outcome measures.

    The mean and standard deviation of outcome measures. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 163
    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>

    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

    Published 2025
    “…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
    Save to List
    Saved in:
  4. 164
    RcbA and RcbB co-operatively decrease motility independent of CaCl<sub>2</sub> concentration.

    RcbA and RcbB co-operatively decrease motility independent of CaCl<sub>2</sub> concentration. by Shobnom Mustaree (21728815)

    Published 2025
    Save to List
    Saved in:
  5. 165
    Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon.

    Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon. by Daisuke Sugahara (2047696)

    Published 2025
    Save to List
    Saved in:
  6. 166
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 167
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 168
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 169
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 170
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 171
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 172
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 173
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 174
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 175
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 176
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 177
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 178
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 179
    Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescriptions).

    Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  20. 180
    Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n = 269.151prescriptions).

    Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:

Search Tools: